Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Melody A. Cobleigh"'
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Autor:
Vincent Antao, Mohammad Jahanzeb, Denise A. Yardley, Joyce O'Shaughnessy, Peter A. Kaufman, Ginny Mason, Adam Brufsky, Sara A. Hurvitz, Laura Chu, Melody A. Cobleigh, Hope S. Rugo, Sandra M. Swain, Debu Tripathy, Haocheng Li
Publikováno v:
Clinical Cancer Research. 26:1105-1113
Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs).
Autor:
James N. Ingle, George Thomas Budd, William C. Wood, Silvana Martino, Melody A. Cobleigh, Larry Norton, Mark L. Graham, Ruta D. Rao, Robert Gray
Publikováno v:
Medical Oncology. 28:39-47
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide. Between Oct
Autor:
Melody A. Cobleigh, Susan Moore
Publikováno v:
Seminars in Oncology Nursing. 23:37-45
Objectives To review the chemotherapy and targeted biologic options for treatment of advanced and metastatic breast cancer. Data Sources Clinical and research articles and textbook chapters. Conclusion Recent clinical research has led to the use of n
Autor:
J Wolter, Korenblit Ad, Bruce C. McLeod, S G Taylor th, Carol M. Richman, Melody A. Cobleigh, Sharon Manson, Leonard A. Valentino, Richard G. Ghalie, Adler Ss
Publikováno v:
Journal of Clinical Oncology. 12:342-346
PURPOSE We investigated the role of high-dose chemotherapy and autologous bone marrow transplantation (ABMT) as the initial systemic treatment in patients with hormone-unresponsive metastatic breast cancer. We studied a regimen involving a split-cour
Autor:
William Novotny, Virginia K. Langmuir, Amy Vassel, James D. Reimann, Latrice Haney, Melody A. Cobleigh, Kathy D. Miller, George W. Sledge
Publikováno v:
Seminars in oncology. 30(5 Suppl 16)
Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic ag
Autor:
Lynn M. Schuchter, H. Rasmussen, Nicholas J. Robert, Kathy D. Miller, Joseph A. Sparano, George W. Sledge, Melody A. Cobleigh, William J. Gradishar
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 13(8)
Background This pilot trial was performed to evaluate the safety, toxicity and pharmacokinetics of chronic therapy with the matrix metalloproteinase inhibitor marimastat in the adjuvant treatment of breast cancer. Patients and methods Patients with h
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(5)
PURPOSE Adjuvant chemotherapy for breast cancer causes significant changes in ovarian function. More young women survive breast cancer than ever before and they are at risk of the sequelae of early menopause. We attempted to (1) define menopausal sta
Autor:
R G Mehta, J B Ashenhurst, Alfred W. Rademaker, J L Wade rd, Melody A. Cobleigh, K Dowlatshahi, R C Moon, A B Benson rd, T A Deutsch, F Minn
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(3)
PURPOSE Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more